Biomind Labs Inc. (NEO:BMND)

Canada flag Canada · Delayed Price · Currency is CAD
0.200
0.00 (0.00%)
At close: Apr 24, 2026
-42.86%
Market Cap 11.12M
Revenue (ttm) n/a
Net Income (ttm) -1.17M
Shares Out n/a
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,023
Average Volume 6,181
Open 0.200
Previous Close 0.200
Day's Range 0.200 - 0.200
52-Week Range 0.010 - 0.320
Beta -0.14
RSI 51.11
Earnings Date May 14, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange Cboe Canada
Ticker Symbol BMND
Full Company Profile

Financial Performance

Financial numbers in USD

News

There is no news available yet.